Mats Jerkeman
11 – 20 of 200
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Inter-reader agreement of quantitative FDG PET/CT biomarkers in lymphoma : a multicentre evaluation of MTV, TLG and Dmax
- Contribution to journal › Article
-
Mark
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma : a Danish population-based study
- Contribution to journal › Article
- 2024
-
Mark
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia☆
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Contribution to journal › Article
-
Mark
Tattoos as a risk factor for malignant lymphoma: a population-based case–control study
- Contribution to journal › Article
-
Mark
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
- Contribution to journal › Article
-
Mark
Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden : the Obesity and Disease Development Sweden (ODDS) pooled cohort study
- Contribution to journal › Article
-
Mark
The National Swedish Lymphoma Register – a systematic validation of data quality
- Contribution to journal › Article
-
Mark
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression
- Contribution to journal › Article
